Abstract： Objective： To observe the clinical effect of Yifei Qinghua Granules combined with platinum-based doublet chemotherapy regimen and Camrelizumab on advanced non-small cell lung cancer （NSCLC） and its effect on cytotoxic T （Tc） cells. Methods：A total of 110 cases of patients with advanced NSCLC were divided into the control group and the observation group according to the random number table method，with 55 cases in each group. The control group was treated with platinum-based doublet chemotherapy regimen and Camrelizumab， and the observation group was additionally treated with Yifei Qinghua Granules in addition to the treatment given to the control group. The traditional Chinese medicine （TCM） syndrome scores， immune function-related indicators [Tc cells， natural killer （NK） cells，and regulatory T （Treg） cells]，adverse reactions，and clinical effects were compared between the two groups. Results：The objective remission rate and disease control rate were 65.45%（36/55） and 94.55%（52/55） respectively in the observation group and 36.36%（20/55） and 80.00%（44/55） respectively in the control group，with significant differences between the two groups （P＜0.05）. After treatment，TCM syndrome scores in the two groups were decreased when compared with those before treatment （P＜0.05）， with the observation group scoring lower than the control group （P＜0.05）. After treatment， the proportions of Tc and NK cells in the two groups were increased when compared with those before treatment （P＜0.05）， and the proportions of Treg cells were decreased （P＜0.05）； the observation group had higher proportions of Tc and NK cells and a lower proportion of Treg cells compared to the control group（ P＜0.05）. The incidence of adverse reactions was 21.82%（12/55）in the observation group and 41.82%（23/55）in the control group， with a significant difference between the two groups （P＜0.05）. Conclusion： Yifei Qinghua Granules combined with platinum-based doublet chemotherapy regimen and Camrelizumab can enhance clinical efficacy，effectively improve TCM syndromes and immune function，and reduce the toxic side effects of chemotherapy in the treatment of advanced NSCLC.